Publications by authors named "Michael Whaby"

Article Synopsis
  • - The RAS family GTPases are a key group of oncogenes frequently mutated in human cancers, with mutations found in about 20% of tumors, particularly NRAS mutations present in about 25% of melanomas.
  • - Current therapies have targeted KRAS mutations effectively, but there is a significant lack of treatments specifically aimed at NRAS, making it a critical area for developing new cancer therapies.
  • - This study introduces a new monobody that can bind to both forms of NRAS and inhibit its signaling, offering a promising direction for creating selective inhibitors and potential therapeutics for NRAS and BRAF-mutant melanomas.
View Article and Find Full Text PDF

Missense mutations in the RAS family of oncogenes (HRAS, KRAS, and NRAS) are present in approximately 20% of human cancers, making RAS a valuable therapeutic target (Prior et al., Cancer Res 80:2969-2974, 2020). Although decades of research efforts to develop therapeutic inhibitors of RAS were unsuccessful, there has been success in recent years with the entrance of FDA-approved KRAS-specific inhibitors to the clinic (Skoulidis et al.

View Article and Find Full Text PDF

The G12D mutation is among the most common KRAS mutations associated with cancer, in particular, pancreatic cancer. Here, we have developed monobodies, small synthetic binding proteins, that are selective to KRAS(G12D) over KRAS(wild type) and other oncogenic KRAS mutations, as well as over the G12D mutation in HRAS and NRAS. Crystallographic studies revealed that, similar to other KRAS mutant-selective inhibitors, the initial monobody bound to the S-II pocket, the groove between switch II and α3 helix, and captured this pocket in the most widely open form reported to date.

View Article and Find Full Text PDF

Mutations in one of the three RAS genes (HRAS, KRAS, and NRAS) are present in nearly 20% of all human cancers. These mutations shift RAS to the GTP-loaded active state due to impairment in the intrinsic GTPase activity and disruption of GAP-mediated GTP hydrolysis, resulting in constitutive activation of effectors such as RAF. Because activation of RAF involves dimerization, RAS dimerization has been proposed as an important step in RAS-mediated activation of effectors.

View Article and Find Full Text PDF

RAS proteins represent critical drivers of tumor development and thus are the focus of intense efforts to pharmacologically inhibit these proteins in human cancer. Although recent success has been attained in developing clinically efficacious inhibitors to KRAS, there remains a critical need for developing approaches to inhibit additional mutant RAS proteins. A number of anti-RAS biologics have been developed which reveal novel and potentially therapeutically targetable vulnerabilities in oncogenic RAS.

View Article and Find Full Text PDF

The phenoxazine dye resazurin exhibits bactericidal activity against the Gram-negative pathogens and . One resazurin derivative, resorufin pentyl ether, significantly reduces vaginal colonization by in a mouse model of infection. The narrow spectrum of bacteria susceptible to resazurin and its derivatives suggests these compounds have a novel mode of action.

View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_sessionig0d5i0k4mfslmep6pshbdouepea22ls): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once